How AstraZeneca plc Can Pay Off Your Mortgage

AstraZeneca plc (LON: AZN) has potential. And it could help pay off your mortgage. Here’s how.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaWhat a difference a year makes! Shares in AstraZeneca (LSE: AZN) (NYSE: AZN.US) are now 30% higher than they were just one year ago, with the performance of the pharmaceutical company easily beating the 1% gains of the FTSE 100 over the same time period.

So, what’s changed? Clearly, AstraZeneca’s share price has benefited hugely from the bid approaches from Pfizer, with it still appearing to include a takeover premium of sorts. However, this isn’t the full story, since the market’s perception of where AstraZeneca is headed has changed considerably since a year ago, with the future now looking a lot brighter. As such, AstraZeneca could be a great long-term play.

Falling Earnings

Of course, the ‘patent cliff’ still exists, where AstraZeneca is due to lose patent protection on a number of key, blockbuster drugs in the short run. This has hurt profits and will continue to do so for another couple of years. Indeed, AstraZeneca’s earnings per share (EPS) fell by 26% last year and are forecast to drop by another 14% in the current year. Although better, next year is still due to see a fall of 3%, which shows that the company remains in a difficult place right now.

Future Potential

However, AstraZeneca’s future looks much brighter now than a year or two ago. That’s because it has focused on rejuvenating its drug pipeline through a number of key acquisitions. An example is the purchase of Bristol-Myers Squibb‘s half of the two companies’ diabetes joint venture. This should help AstraZeneca to grow the top and bottom line over the long run, as the number of people with diabetes in the US alone is set to increase by 165% from the year 2000 to the year 2050. Further deals look likely, with AstraZeneca’s new management team ending the superfluous share buyback scheme. This allows more capital to be spent on developing the drug pipeline.

Looking Ahead

Certainly, AstraZeneca’s share price is not as attractive at £43 as it was at £33 one year ago. However, the company is in better shape and so the current price to earnings (P/E) ratio of 17.1 does not appear to be excessive for long-term investors. Clearly, a lack of further bid activity could cause the share price to weaken in the short run, but with an improving pipeline and the scope for more acquisitions, AstraZeneca could be a long-term winner and, as such, could help to pay off your mortgage.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares in AstraZeneca. The Motley Fool has no position in any of the shares mentioned.

More on Investing Articles

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »

Investing Articles

1 under the radar FTSE 100 AI stock investors should consider buying

Our writer explains why this FTSE 100 pick could be a shrewd investment with its established experience of using AI…

Read more »

Investing Articles

Does the beaten-down Diageo share price make it a no-brainer buy?

Harvey Jones spent years waiting for the Diageo share price to look like good value, before finally buying it in…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

8%+ yields! Should I buy these FTSE 100 income shares this month?

Christopher Ruane weighs some pros and cons of two FTSE 100 shares, both of which have a dividend yield over…

Read more »